AKT collaborates with ERG and Gata1s to dysregulate megakaryopoiesis and promote AMKL

The requirement that leukemic GATA1 mutations be present in cells harboring trisomy 21 led to the discovery that overexpression of ERG drives aberrant megakaryopoiesis. Given that constitutive PI3K/AKT signaling is a frequent component of hematologic malignancies and the relationship between AKT and Notch in this lineage, we studied the cross talk between AKT signaling and ERG in megakaryopoiesis. We discovered that constitutive AKT signaling is associated with a dramatic increase in apoptosis of WT MKs, but that overexpression of ERG blocks AKT-induced death. We further found that Gata1 mutations protect megakaryocytes from activated AKT-induced apoptosis. As a consequence, however, the enhanced signaling inhibits differentiation of Gata1 mutant, but not WT, megakaryocytes. Gata1 mutant cells that overexpress ERG with hyperactive AKT are characterized by diminished FOXO1/3a expression and an increased dependency on the c-Jun pathway similar to that seen in AMKL cell lines, AML with knockdown of FOXO3a, or AML with expression of myrAKT. Additionally, we found that the AKT allosteric inhibitor MK2206 caused reduced cell viability and proliferation of AMKL cell lines. The contribution of aberrant AKT signaling during the ontogeny of DS-TMD/AMKL indicates that AKT is a therapeutic target in this form of AML.